Gastrointestinal Drugs Market Analysis, Opportunities by 2031
The gastrointestinal drugs market size is projected to reach US$ 106,304.81 million by 2031 from US$ 59,713.68 million in 2023. The market is expected to register a CAGR of 5.4% during 2023–2031. Increasing research investment for novel drug development and artificial intelligence-based techniques is likely to bring new trends in the gastrointestinal drugs market in the coming years.
Gastrointestinal Drugs Market Analysis
The factors driving the gastrointestinal drugs market include the growing cases of chronic constipation among all age groups, a surge in sales of over-the-counter remedies, a growing need for laxatives, and increasing product offerings from manufacturers. Pharmaceutical companies are investing in research and development aimed at creating new and more effective gastrointestinal medications. Rising investments in the development of biologics and the introduction of biosimilars are fueling the expansion of the market for gastrointestinal drugs. The advancements and improved gastrointestinal drugs have resulted in the creation of innovative drugs that offer better results, improved tolerability, and reduced adverse effects. With heightened patient awareness, there is also a greater demand for medications that can effectively manage symptoms and enhance the patient's overall well-being. Moreover, the presence of state-of-the-art medical facilities and high spending on healthcare are boosting the growth of the gastrointestinal drugs market.
Gastrointestinal Drugs Market Overview
The market growth is ascribed to the rising prevalence of gastrointestinal disorders, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), along with a surge in research and development activities, leading to the innovation of advanced therapeutics for the treatment of various gastrointestinal conditions. In April 2021, Intract Pharma Limited initiated a collaborative research program with Ferring Pharmaceuticals to investigate oral delivery of a monoclonal antibody (mAb) targeting an undisclosed interleukin for the treatment of IBD. The research focuses on the evaluation of Intract’s Phloral and Soteria technologies for precision oral delivery of the therapeutic mAb directly to gastrointestinal tissue to improve efficacy and minimize systemic exposure.
Increasing awareness campaigns in the UK lead to increased awareness among a large population and fuel the demand for gastrointestinal drugs for the treatment of various gastrointestinal disorders. For instance, Takeda Pharmaceuticals created the “In My Shoes” app in collaboration with Crohn’s and Colitis UK to increase awareness about the need for more consistent care for patients suffering from IBD across the country.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Gastrointestinal Drugs Market: Strategic Insights
Market Size Value in US$ 49,043.38 million in 2019 Market Size Value by US$ 71,300.28 Million by 2027 Growth rate CAGR of 5.4% from 2020 to 2027 Forecast Period 2020 - 2027 Base Year 2019
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Gastrointestinal Drugs Market: Strategic Insights
| Market Size Value in | US$ 49,043.38 million in 2019 |
| Market Size Value by | US$ 71,300.28 Million by 2027 |
| Growth rate | CAGR of 5.4% from 2020 to 2027 |
| Forecast Period | 2020 - 2027 |
| Base Year | 2019 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Gastrointestinal Drugs Market Drivers and Opportunities
Improving Development of Biologics Favors Market Growth
In the past few years, there has been a rise in the development of advanced new treatments, such as biologics, which are utilized for the treatment of inflammatory diseases. In addition, biologics have transformed the IBD treatment, and their success in the treatment of these conditions, which supports the use of biologics in other gastrointestinal conditions. Biologics are also effective in treating eosinophilic esophagitis, celiac disease, autoimmune hepatitis, and other gastrointestinal diseases, as they target the disease-causing elements in the immune system. Many ulcerative colitis medications have wide-ranging effects on the immune system. To block such effects of the inflammatory process, biologics are widely used. One such group of biologic drugs for ulcerative colitis is known as anti-TNF drugs that block a protein called tumor necrosis factor-alpha (TNF alpha). This protein promotes inflammation in the intestines and specific other organs. Anti-TNF agents were the first class of biologics to be authorized for IBD treatment and have tremendously changed IBD management. A few types of anti-TNF drugs include Humira, Simponi, and Remicade. A variety of biological drugs can reduce IBD symptoms in adults and help achieve remission. Biologic medications can be an effective substitute to help control the symptoms of ulcerative colitis. The FDA has approved many biologic drugs such as Humira (adalimumab), Cimzia, Simponi (golimumab), Tysabri, Remicade (infliximab), Entyvio (Vedolizumab), and Stelara (ustekinumab) for the treatment of Crohn’s disease and ulcerative colitis.
Many companies are involved in developing a wide range of biological drugs. In July 2020, Takeda Pharmaceutical launched the biologic drug—Vedolizumab—as part of its gastrointestinal portfolio in India. Vedolizumab is sold in the country under the brand name Kynteles. It is used to treat a variety of chronic IBD. Vedolizumab has become the first choice among second-line biologics for the treatment of moderate to severe Crohn's disease and ulcerative colitis patients who have experienced failure with conventional medications or anti-TNF agents. In February 2024, Celltrion Healthcare’s Remsima SC obtained approval from Health Canada for its use as maintenance therapy for IBD. As cases of gastrointestinal disease are on the rise in developing countries, new biologics are introduced in these markets. Thus, the increasing development of biologics for treating gastrointestinal diseases drives the gastrointestinal drugs market.
Strategic Initiatives by Companies
Companies operating in the gastrointestinal drugs market constantly focus on strategic developments, which help them improve their sales, increase their geographic reach, and improve their capacities to cater to a greater than existing customer base. A few strategic initiatives taken by key players operating in the gastrointestinal drugs market are mentioned below:
• On April 19, 2024, Takeda received US Food and Drug Administration (FDA) approval for ENTYVIO (vedolizumab) subcutaneous administration as a maintenance therapy to treat adults suffering from mild to severe active Crohn’s disease. FDA also approved the subcutaneous administration of the same drug in September 2023 for the treatment of adults diagnosed with moderate to severe ulcerative colitis, and it is available as a single-dose prefilled pen in the US.
• In October 2023, Eli Lilly and Company received US FDA approval for Omvoh (mirikizumab) infusion/injection, the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderate to severe ulcerative colitis in adults. Unlike existing treatments, mirikizumab also provides relief from a key symptom—bowel urgency—that significantly impacts patients’ quality of life.
• In September 2023, Vivante Health closed US$ 31 million in a Series B funding round led by Mercato Partners, a new investor, to advance the digital digestive health platform. The new funding is mainly received due to the latest GIThrive platform enhancements that highlight the platform's unique ability to provide proper care at the right time. Series B Capital provides continued technological advancements designed to predict the onset and progression of gastrointestinal conditions and provide complete virtual care.
Therefore, strategic initiatives by various companies focusing on developing drugs for treating digestive diseases are likely to offer lucrative opportunities for the gastrointestinal drugs market growth in the coming years.
Gastrointestinal Drugs Market Report Segmentation Analysis
Key segments that contributed to the derivation of the gastrointestinal drugs market analysis are drug class, application, route of administration, and distribution channel.
- Based on drug class, the gastrointestinal drugs market is categorized into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, and others. The biologics segment held the largest share of the market in 2023. The antiemetic and antinauseants segment is expected to register the highest CAGR in the market during 2023–2031.
- By application, the gastrointestinal drugs market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn’s disease, gastroenteritis, celiac disease, and others. The irritable bowel syndrome segment held the largest share of the market in 2023. The gastroenteritis segment is projected to register the highest CAGR in the market during 2023–2031.
- Based on route of administration, the market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2023, and it is expected to register a higher CAGR in the market during the forecast period.
- In terms of distribution channel, the gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2023 and is anticipated to register the highest CAGR during 2023–2031.
Gastrointestinal Drugs Market Share Analysis by Geography
The geographic scope of the gastrointestinal drugs market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America held a significant share of the market in 2023. The growth of the market in this region is attributed to the rising incidence of gastrointestinal diseases and the existence of governmental and nongovernmental organizations supporting research efforts for gastrointestinal treatments. In addition, the involvement of numerous market players, along with different strategic initiatives undertaken by them, are boosting the growth of the market in the region. In addition, easy availability of products and heightened awareness among patients are a few of the other factors contributing to the expansion of the market across North America.
Gastrointestinal Drugs Market Report Scope
Gastrointestinal Drugs Market News and Recent Developments
The gastrointestinal drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the gastrointestinal drugs market are listed below:
- Bayer Consumer Health introduced Iberogast, a plant-based digestive relief product, to millions of people in the US who experience gut health issues. Formulated with a clinically proven, proprietary six-herb blend, Iberogast harnesses the power of nature to provide dual-action relief for those who experience occasional digestive symptoms by helping to relieve stomach upsets and restore digestive function. (Source: Bayer AG, Press Release, April 2024)
- AbbVie Inc. and Landos Biopharma, Inc. entered into a definitive agreement under which AbbVie acquired Landos, a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist with a bimodal mechanism of action, which is anti-inflammatory and facilitates epithelial repair. (Source: AbbVie Inc., Press Release, March 2024)
Gastrointestinal Drugs Market Report Coverage and Deliverables
The “Gastrointestinal Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Gastrointestinal drugs market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Gastrointestinal drugs market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Gastrointestinal drugs market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the gastrointestinal drugs market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Drug Class, Route of Administration, Application, and Distribution Channel
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The global gastrointestinal drugs market is estimated to register a CAGR of 7.5% during the forecast period.
The estimated value of the gastrointestinal drugs market can reach US$ 1,06,304.81 million by 2031.
North America dominated the gastrointestinal drugs market in 2023.
The rising incidence of gastrointestinal diseases and increasing development of biologics are the most influential factors responsible for the market growth.
Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Pfizer Inc, and Celltrion Inc. are among the key players operating in the gastrointestinal drugs market.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. Gastrointestinal Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Gastrointestinal Drugs Market – Key Market Dynamics
5.1 Gastrointestinal Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Cases of Gastrointestinal Diseases
5.2.2 Increasing Development of Biologics
5.3 Market Restraints
5.3.1 High Cost of Biologics
5.3.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
5.4 Market Opportunities
5.4.1 Strategic Initiatives by Companies
5.5 Future Trends
5.5.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
5.6 Impact of Drivers and Restraints:
6. Gastrointestinal Drugs Market – Global Market Analysis
6.1 Gastrointestinal Drugs Market Revenue (US$ Million), 2021–2031
6.2 Gastrointestinal Drugs Market Forecast Analysis
7. Gastrointestinal Drugs Market Analysis – by Drug Class
7.1 Biologics
7.1.1 Overview
7.1.2 Biologics: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Antidiarrheal and Laxatives
7.2.1 Overview
7.2.2 Antidiarrheal and Laxatives: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Acid Neutralizers
7.3.1 Overview
7.3.2 Acid Neutralizers: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Anti-inflammatory Drugs
7.4.1 Overview
7.4.2 Anti-inflammatory Drugs: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Antiemetic and Antinauseants
7.5.1 Overview
7.5.2 Antiemetic and Antinauseants: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8. Gastrointestinal Drugs Market Analysis – by Application
8.1 Irritable Bowel Syndrome
8.1.1 Overview
8.1.2 Irritable Bowel Syndrome: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Inflammatory Ulcerative Colitis
8.2.1 Overview
8.2.2 Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Crohns Disease
8.3.1 Overview
8.3.2 Crohns Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Gastroenteritis
8.4.1 Overview
8.4.2 Gastroenteritis: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Celiac Disease
8.5.1 Overview
8.5.2 Celiac Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9. Gastrointestinal Drugs Market Analysis – by Route Of Administration
9.1 Oral
9.1.1 Overview
9.1.2 Oral: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Parenteral
9.2.1 Overview
9.2.2 Parenteral: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10. Gastrointestinal Drugs Market Analysis – by Distribution Channel
10.1 Hospital Pharmacies
10.1.1 Overview
10.1.2 Hospital Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Retail Pharmacies
10.2.1 Overview
10.2.2 Retail Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
10.3.1 Overview
10.3.2 Online Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11. Gastrointestinal Drugs Market – Geographical Analysis
11.1 North America
11.1.1 North America Gastrointestinal Drugs Market Overview
11.1.2 North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.1.2.1 North America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Drug Class
11.1.2.2 North America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Application
11.1.2.3 North America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
11.1.2.4 North America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
11.1.3 North America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Country
11.1.3.1 United States: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.1.3.1.1 United States: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.1.3.1.2 United States: Gastrointestinal Drugs Market Breakdown, by Application
11.1.3.1.3 United States: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.1.3.1.4 United States: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.1.3.2 Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.1.3.2.1 Canada: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.1.3.2.2 Canada: Gastrointestinal Drugs Market Breakdown, by Application
11.1.3.2.3 Canada: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.1.3.2.4 Canada: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.1.3.3 Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.1.3.3.1 Mexico: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.1.3.3.2 Mexico: Gastrointestinal Drugs Market Breakdown, by Application
11.1.3.3.3 Mexico: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.1.3.3.4 Mexico: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.2 Europe
11.2.1 Europe Gastrointestinal Drugs Market Overview
11.2.2 Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2.2.1 Europe: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Drug Class
11.2.2.2 Europe: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Application
11.2.2.3 Europe: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
11.2.2.4 Europe: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
11.2.3 Europe: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Country
11.2.3.1 Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.1.1 Germany: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.2.3.1.2 Germany: Gastrointestinal Drugs Market Breakdown, by Application
11.2.3.1.3 Germany: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.2.3.1.4 Germany: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.2.3.2 United Kingdom: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.2.1 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.2.3.2.2 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Application
11.2.3.2.3 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.2.3.2.4 United Kingdom: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.2.3.3 France: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.3.1 France: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.2.3.3.2 France: Gastrointestinal Drugs Market Breakdown, by Application
11.2.3.3.3 France: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.2.3.3.4 France: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.2.3.4 Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.4.1 Italy: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.2.3.4.2 Italy: Gastrointestinal Drugs Market Breakdown, by Application
11.2.3.4.3 Italy: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.2.3.4.4 Italy: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.2.3.5 Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.5.1 Spain: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.2.3.5.2 Spain: Gastrointestinal Drugs Market Breakdown, by Application
11.2.3.5.3 Spain: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.2.3.5.4 Spain: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.2.3.6 Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2.3.6.1 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.2.3.6.2 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Application
11.2.3.6.3 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.2.3.6.4 Rest of Europe: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.3 Asia Pacific
11.3.1 Asia Pacific Gastrointestinal Drugs Market Overview
11.3.2 Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3.2.1 Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Drug Class
11.3.2.2 Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Application
11.3.2.3 Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
11.3.2.4 Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
11.3.3 Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Country
11.3.3.1 China: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.1.1 China: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.3.3.1.2 China: Gastrointestinal Drugs Market Breakdown, by Application
11.3.3.1.3 China: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.3.3.1.4 China: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.3.3.2 Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.2.1 Japan: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.3.3.2.2 Japan: Gastrointestinal Drugs Market Breakdown, by Application
11.3.3.2.3 Japan: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.3.3.2.4 Japan: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.3.3.3 India: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.3.1 India: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.3.3.3.2 India: Gastrointestinal Drugs Market Breakdown, by Application
11.3.3.3.3 India: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.3.3.3.4 India: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.3.3.4 Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.4.1 Australia: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.3.3.4.2 Australia: Gastrointestinal Drugs Market Breakdown, by Application
11.3.3.4.3 Australia: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.3.3.4.4 Australia: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.3.3.5 South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.5.1 South Korea: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.3.3.5.2 South Korea: Gastrointestinal Drugs Market Breakdown, by Application
11.3.3.5.3 South Korea: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.3.3.5.4 South Korea: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.3.3.6 Rest of APAC: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.3.3.6.1 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.3.3.6.2 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Application
11.3.3.6.3 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.3.3.6.4 Rest of APAC: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.4 Middle East & Africa
11.4.1 Middle East & Africa Gastrointestinal Drugs Market Overview
11.4.2 Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.4.2.1 Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Drug Class
11.4.2.2 Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Application
11.4.2.3 Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
11.4.2.4 Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
11.4.3 Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Country
11.4.3.1 Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.1.1 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.4.3.1.2 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Application
11.4.3.1.3 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.4.3.1.4 Saudi Arabia: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.4.3.2 South Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.2.1 South Africa: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.4.3.2.2 South Africa: Gastrointestinal Drugs Market Breakdown, by Application
11.4.3.2.3 South Africa: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.4.3.2.4 South Africa: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.4.3.3 United Arab Emirates: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.3.1 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.4.3.3.2 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Application
11.4.3.3.3 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.4.3.3.4 United Arab Emirates: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.4.3.4 Rest of Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.4.3.4.1 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.4.3.4.2 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Application
11.4.3.4.3 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.4.3.4.4 Rest of Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.5 South & Central America
11.5.1 South & Central America Gastrointestinal Drugs Market Overview
11.5.2 South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.5.2.1 South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Drug Class
11.5.2.2 South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Application
11.5.2.3 South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Route Of Administration
11.5.2.4 South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Distribution Channel
11.5.3 South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast Analysis – by Country
11.5.3.1 Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.1.1 Brazil: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.5.3.1.2 Brazil: Gastrointestinal Drugs Market Breakdown, by Application
11.5.3.1.3 Brazil: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.5.3.1.4 Brazil: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.5.3.2 Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.2.1 Argentina: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.5.3.2.2 Argentina: Gastrointestinal Drugs Market Breakdown, by Application
11.5.3.2.3 Argentina: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.5.3.2.4 Argentina: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
11.5.3.3 Rest of South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.5.3.3.1 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Drug Class
11.5.3.3.2 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Application
11.5.3.3.3 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Route Of Administration
11.5.3.3.4 Rest of South & Central America: Gastrointestinal Drugs Market Breakdown, by Distribution Channel
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in Gastrointestinal Drugs Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Sanofi SA
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GSK Plc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Johnson & Johnson
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bausch Health Companies Inc
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 AstraZeneca Plc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Takeda Pharmaceutical Co Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 AbbVie Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Bayer AG
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Celltrion Inc
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Pfizer Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
List of Tables
Table 1. Gastrointestinal Drugs Market Segmentation
Table 2. North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 3. North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 4. North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 5. North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 6. United States: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 7. United States: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 8. United States: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 9. United States: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 10. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 11. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 12. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 13. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 14. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 15. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 16. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 17. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 18. Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 19. Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 20. Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 21. Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 22. Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 23. Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 24. Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 25. Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 26. United Kingdom: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 27. United Kingdom: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 28. United Kingdom: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 29. United Kingdom: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 30. France: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 31. France: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 32. France: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 33. France: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 34. Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 35. Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 36. Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 37. Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 38. Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 39. Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 40. Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 41. Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 42. Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 43. Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 44. Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 45. Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 46. Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 47. Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 48. Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 49. Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 50. China: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 51. China: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 52. China: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 53. China: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 54. Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 55. Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 56. Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 57. Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 58. India: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 59. India: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 60. India: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 61. India: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 62. Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 63. Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 64. Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 65. Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 66. South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 67. South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 68. South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 69. South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 70. Rest of APAC: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 71. Rest of APAC: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 72. Rest of APAC: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 73. Rest of APAC: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 74. Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 75. Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 76. Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 77. Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 78. Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 79. Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 80. Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 81. Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 82. South Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 83. South Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 84. South Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 85. South Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 86. United Arab Emirates: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 87. United Arab Emirates: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 88. United Arab Emirates: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 89. United Arab Emirates: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 90. Rest of Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 91. Rest of Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 92. Rest of Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 93. Rest of Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 94. South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 95. South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 96. South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 97. South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 98. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 99. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 100. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 101. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 102. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 103. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 104. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 105. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 106. Rest of South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Drug Class
Table 107. Rest of South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Application
Table 108. Rest of South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Route Of Administration
Table 109. Rest of South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million) – by Distribution Channel
Table 110. Recent Organic Growth Strategies in Gastrointestinal Drugs Market
Table 111. Recent Inorganic Growth Strategies in the Gastrointestinal Drugs Market
Table 112. Glossary of Terms, Gastrointestinal Drugs Market
List of Figures
Figure 1. Gastrointestinal Drugs Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Gastrointestinal Drugs Market Revenue (US$ Million), 2021–2031
Figure 5. Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 6. Gastrointestinal Drugs Market Share (%) – by Drug Class (2023 and 2031)
Figure 7. Biologics: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Antidiarrheal and Laxatives: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Acid Neutralizers: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Anti-inflammatory Drugs: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Antiemetic and Antinauseants: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Gastrointestinal Drugs Market Share (%) – by Application (2023 and 2031)
Figure 14. Irritable Bowel Syndrome: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Inflammatory Ulcerative Colitis: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Crohns Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Gastroenteritis: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Celiac Disease: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Others: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gastrointestinal Drugs Market Share (%) – by Route Of Administration (2023 and 2031)
Figure 21. Oral: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Parenteral: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Gastrointestinal Drugs Market Share (%) – by Distribution Channel (2023 and 2031)
Figure 24. Hospital Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. Retail Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. Online Pharmacies: Gastrointestinal Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. North America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 28. North America: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 29. United States: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 30. Canada: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 31. Mexico: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 32. Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 33. Europe: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 34. Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 35. United Kingdom: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 36. France: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 37. Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 38. Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 39. Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 40. Asia Pacific: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 41. Asia Pacific: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 42. China: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 43. Japan: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 44. India: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 45. Australia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 46. South Korea: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 47. Rest of APAC: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 48. Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 49. Middle East & Africa: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 50. Saudi Arabia: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 51. South Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 52. United Arab Emirates: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 53. Rest of Middle East & Africa: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 54. South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 55. South & Central America: Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 56. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 57. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 58. Rest of South & Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2031(US$ Million)
Figure 59. Growth Strategies in Gastrointestinal Drugs Market
The List of Companies - Gastrointestinal Drugs Market
- Sanofi SA
- GSK Plc
- Johnson & Johnson
- Bausch Health Companies Inc
- AstraZeneca Plc
- Takeda Pharmaceutical Co Ltd
- AbbVie Inc
- Bayer AG
- Celltrion Inc
- Pfizer Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For